France· FR:62056415
PONVORY 20 mg, comprimé pelliculé
A medicinal product containing ponésimod, registered in France by LABORATOIRES JUVISE PHARMACEUTICALS, on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- PONÉSIMOD
- Manufacturer
- LABORATOIRES JUVISE PHARMACEUTICALS
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930232224plaquette(s) thermoformée(s) OPA : polyamide orienté aluminium polyéthylène polytéréphtalate (PET) de 28 comprimé(s)EUR 620.85
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ponésimod in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPONVORYLaboratoires Juvisé Pharmaceuticals, Villeurbanne
- United StatesPONVORYVanda Pharmaceuticals Inc.
- SpainPONVORY 20 mg COMPRIMIDOS RECUBIERTOS CON PELICULALaboratoires Juvise Pharmaceuticals
- FinlandPonvoryLaboratoires Juvise Pharmaceuticals
- IrelandPonvory 20 mg film-coated tabletsLaboratoires Juvise Pharmaceuticals
- BelgiumPonvory 20 mgLaboratoires Juvise Pharmaceuticals
- NetherlandsPonvory 20 mg filmomhulde tablettenLaboratoires Juvise Pharmaceuticals
- NorwayPonvoryLABORATOIRES JUVISE PHARMACEUTICALS
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ponvory
- Liechtenstein · Ponvory
- Norway · Ponvory
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6dfc32e5-c159-442b-bd71-49110d3de2d8 GET /v1/drugs/6dfc32e5-c159-442b-bd71-49110d3de2d8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62056415",
"date_amm": "2021-05-19",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/21/1550",
"substance": "PONÉSIMOD",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about ponésimod.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.